Brevan Howard Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Brevan Howard Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-133,315	Closed	-$409K	–	2511
2026 Q1	$409K	Buy	+133,315	New	+$515K	﹤0.01%	1425
2025 Q4	–	Sell	-30,159	Closed	-$147K	–	2213
2025 Q3	$147K	Sell	30,159 -83,039	-73%	-$436K	﹤0.01%	1815
2025 Q2	$573K	Sell	113,198 -143,803	-56%	-$706K	﹤0.01%	1301
2025 Q1	$1.36M	Buy	257,001 +216,910	+541%	+$1.58M	0.01%	395
2024 Q4	$271K	Buy	+40,091	New	+$270K	﹤0.01%	814
2024 Q2	–	Sell	-21,096	Closed	-$210K	–	1360
2024 Q1	$210K	Buy	+21,096	New	+$235K	﹤0.01%	784

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Brevan Howard Capital Management's RXRX Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 133,315 shares — an estimated $409K sold.

Brevan Howard Capital Management first reported a position in RXRX in Q1 2024 and held it in 6 quarters. The position peaked at $1.36M in Q1 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Brevan Howard Capital Management reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 133,315 Recursion Pharmaceuticals shares in Q2 2026, an estimated $409K.
Brevan Howard Capital Management first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 6 quarters.
Brevan Howard Capital Management's Recursion Pharmaceuticals position peaked at $1.36M in Q1 2025.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.